Dehydrolithocholic Acid

Most stool tests focus on whether bad bugs are present. This one looks at what your bugs are actually doing to a chemical your liver depends on. Dehydrolithocholic acid (an oxidized form of lithocholic acid) is one of many bile acid molecules that your gut bacteria create from the bile your liver releases after meals.

It is an exploratory marker rather than an established clinical test. There are no consensus cutpoints, no guideline thresholds, and limited direct human research. Even so, the broader bile acid pool it belongs to has been linked to liver disease, kidney disease, gut inflammation, and heart disease, which is why early adopters are starting to track it.

What This Molecule Is

Your liver makes primary bile acids to help digest fat. After those bile acids reach the gut, certain bacteria chemically alter them, producing what scientists call secondary bile acids. Lithocholic acid is one such secondary bile acid. Dehydrolithocholic acid (sometimes called 3-keto-LCA) is a further-modified, oxidized version of lithocholic acid that bacteria produce as part of this same process.

Because microbes are the ones doing the chemistry, the level of this molecule in your stool is a window into who is living in your gut and how active they are at handling bile. When the right bacteria are present and working, you tend to see a richer pool of secondary bile acid forms. When that microbial community is disturbed, the pool shrinks or shifts.

Why the Bile Acid Pool Matters

Direct studies on dehydrolithocholic acid in stool are sparse. Most of the human evidence here comes from studies that measured related lithocholic acid derivatives or the broader secondary bile acid pool. That evidence consistently shows the same theme: when the secondary bile acid pool is disrupted, several diseases tend to be more common.

Liver Disease

Children with non-alcoholic fatty liver disease show reduced levels of multiple oxidized lithocholic acid derivatives, including 7-ketolithocholic acid, 12-ketolithocholic acid, and others, alongside lower levels of bacteria that perform these conversions. In infants with biliary atresia, levels of related lithocholic acid derivatives track with specific gut bacteria linked to liver injury. These studies measured stool or serum bile acid panels rather than dehydrolithocholic acid specifically, but they place this whole family of molecules in the middle of the liver-gut conversation.

Kidney Disease

One of the few studies to actually measure dehydrolithocholic acid in humans found that plasma levels were lower in people with diabetic kidney disease and very low in those with the most protein leaking into their urine, a sign called macroalbuminuria. After accounting for age and how long someone had diabetes, lower plasma dehydrolithocholic acid still tracked with worse kidney damage. This evidence comes from blood, not stool, so it does not directly tell you what your stool reading means, but it suggests this molecule reflects something biologically meaningful.

Gut Inflammation and Function

In ulcerative colitis, irritable bowel syndrome with diarrhea, and Crohn's disease, the secondary bile acid pool is consistently lower in stool while primary bile acids accumulate. Reviews of bile acid biology describe how lithocholic acid and its oxidized cousins act on receptors called TGR5 and FXR (signaling switches that influence gut immune cells, metabolism, and gut motility). A shrunken secondary bile acid pool means less of that signaling reaches its targets.

Heart and Metabolic Health

Large studies of secondary bile acids more broadly have produced mixed but interesting findings. In adults with newly diagnosed type 2 diabetes, higher unconjugated secondary bile acids (especially deoxycholic acid) were tied to higher cardiovascular risk. In coronary artery disease, a different pattern emerged: in 1,730 patients with established disease, higher levels of several unconjugated bile acids were linked to lower mortality. These findings come from blood, not stool, and from related bile acid molecules, not dehydrolithocholic acid itself.

Resolving an Apparent Contradiction

If you read closely, two of the heart studies seem to disagree: one says higher secondary bile acids mean more risk, another says higher unconjugated bile acids mean less mortality. The reconciliation is that bile acids are not a simple high-equals-bad or low-equals-good marker. They are signals about a system. Different molecules in the family do different things, and their meaning depends on which other bile acids are around, what receptors are responding, and what disease is being studied. This is why dehydrolithocholic acid is best read as part of a profile, not as a single number to chase.

Reference Ranges

There are no published clinical reference ranges, decision thresholds, or risk tiers for dehydrolithocholic acid in stool. No major guideline body recommends testing it, and no large population study has established a normal range. Labs that offer this measurement report it alongside other bile acids in a metabolomic-style panel, often using liquid chromatography-mass spectrometry (a sensitive lab technique that separates and identifies small molecules). The most useful approach is to compare your own results within the same lab over time.

Tracking Your Trend

Because no fixed cutpoint exists, a single dehydrolithocholic acid number is hard to interpret on its own. What gives this test value is the trend. Bile acid output shifts with diet, antibiotic exposure, gut bacterial composition, and changes in liver and gut function, all of which can move week to week. Testing once tells you where you sit in a snapshot. Testing again after a meaningful change in diet, body weight, or gut health tells you whether the underlying biology has actually moved.

A reasonable cadence: get a baseline, repeat in three to six months if you are making targeted changes (a different diet, a course of antibiotics, treating a gut infection, or starting new medications that affect bile flow), and at least once a year if your goal is monitoring. Look at dehydrolithocholic acid alongside the other bile acids in the same panel rather than reading it in isolation.

When Results Can Be Misleading

• Recent antibiotics: broad-spectrum antibiotics dramatically reshape the gut bacteria responsible for converting primary bile acids into secondary forms, which can shift the entire bile acid panel for weeks after a course finishes.
• Acute illness or recent diet change: bile acid output responds quickly to what you eat, especially fat content and fiber. A high-fat or low-carbohydrate diet in the days before sample collection can shift bile acid profiles, as shown in human feeding trials.
• Drugs that bind or alter bile acids: bile acid sequestrants like cholestyramine, drugs that injure the liver, and some diabetes medications including SGLT1 inhibitors have been shown to alter the broader bile acid profile in human studies, though specific effects on dehydrolithocholic acid have not been measured.
• Sample handling: stool bile acids are sensitive to time at room temperature and freezing conditions. Follow your lab's collection instructions exactly to avoid distorted readings.

Decision Pathway for Abnormal Results

If your dehydrolithocholic acid result looks unusually low or high, the next move is rarely about that one number. Look at the rest of the bile acid panel: a broadly suppressed secondary bile acid pool with elevated primary bile acids is a different story than an isolated change in one molecule. Pair the bile acid panel with other gut markers like calprotectin (gut inflammation), pancreatic elastase (digestion), and short-chain fatty acids (microbial fermentation activity).

If you also have unexplained digestive symptoms, weight changes, abnormal liver enzymes, or signs of kidney protein leakage, an abnormal pattern here is worth taking to a gastroenterologist or, if liver or kidney markers are also off, a hepatologist or nephrologist. Treat this number as a clue that points toward a fuller workup rather than a diagnosis on its own.